• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Merck KGaA - Articles and news items

ovarian cancer

Phase III trial to evaluate avelumab as first-line treatment in ovarian cancer

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer…

neuroblastoma

Immunotherapy shrinks tumours in neuroblastoma patients

Industry news / 3 June 2016 / Victoria White, Digital Content Producer

Neuroblastoma tumours shrank in 80% of young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody…

syndax

Trial to investigate avelumab and entinostat in ovarian cancer

Industry news / 4 January 2016 / Victoria White

Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells…

avelumab

Merck KGaA and Pfizer advance avelumab clinical development programme

Industry news / 22 December 2015 /

Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer…

Evofosfamide

Evofosfamide fails in two late-stage cancer trials

Industry news / 7 December 2015 / Victoria White

Merck KGaA will also not be pursuing the treatment in pancreatic adenocarcinoma after the drug failed in two late-stage clinical trials…

avelumab

COMP issues positive opinion for ODD for avelumab in MCC

Industry news / 1 December 2015 / Victoria White

An official decision on the Ophran Drug Designation is expected from the European Commission in December…

avelumab

FDA grants Breakthrough Therapy designation to avelumab for MCC

Industry news / 18 November 2015 / Victoria White

Avelumab (MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody…

avelumab

Phase III study of avelumab in NSCLC starts

Industry news / 4 November 2015 / Victoria White

Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer…

avelumab

FDA grants Fast Track designation to avelumab for Merkel cell carcinoma

Industry news / 8 October 2015 / Victoria White

The designation relates to the clinical development programme for avelumab in metastatic MCC, which includes the Phase II study, JAVELIN Merkel 200…

Evofosfamide-pancreatic-cancer

FDA Fast Track designation for evofosfamide for treatment of patients living with advanced pancreatic cancer

Industry news / 12 May 2015 / Victoria White

The FDA has granted Fast Track designation for the development of evofosfamide for the treatment of patients with advanced pancreatic cancer…

avelumab-cancer

Merck KGaA and Pfizer initiate Phase III study with avelumab in patients with stage IIIb/IV non-small cell lung cancer

Industry news / 21 April 2015 / Victoria White

Merck KGaA and Pfizer have announced the initiation and first patient treated in the Phase III study of avelumab compared with docetaxel, in patients NSCLC…

schistosomiasis

Merck supports schistosomiasis education in Mozambique

Industry news / 23 March 2015 / Victoria White

Merck is fighting schistosomiasis in Mozambique, providing WHO with praziquantel tablets free of charge and presenting 20,000 educational brochures…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +